Hepatitis B vaccine boosters: Is there a clinical need in high endemicity populations?

Journal of Gastroenterology and Hepatology (Australia)

Volumn 20, Issue 1, 2005, Pages 5-10

  John, T Jacob ^a,c   Cooksley, Graham ^b   Chan, Veronica F ^d   Chang, Mei Hwei ^e   David, Annette M ^d   Huang, Li Min ^e   Isahak, Ilina ^f   Ismael, Sofyan ^g   Khiem, Ha Ba ^h   Kunasol, Prayura ⁱ   Lung, Lau Yu ^j   Wah, Lee Bee ^k   Lee, Chin Yun ^e   Lolekha, Somsak ^l   Merican, Ismail ^m   Seong, Ng Han ⁿ   Paje Villar, Estrella ^o   Poovorawan, Yong ^p   Sulaiman, H Ali ^g   Young, Betty ^q  

^a Kerala State Inst Virol Infect D   (India)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c College of Public Health University of the Philippines ^*  (India)

^d UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^f DEPARTMENT OF PHARMACOLOGY   (Malaysia)

^g UNIVERSITY OF INDONESIA   (Indonesia)

^h PASTEUR INSTITUTE   (Viet Nam)

ⁱ MINISTRY OF PUBLIC HEALTH   (Thailand)

^j UNIVERSITY OF HONG KONG   (Hong Kong)

^k NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^l MAHIDOL UNIVERSITY   (Thailand)

^m INSTITUTE FOR MEDICAL RESEARCH   (Malaysia)

ⁿ SINGAPORE GENERAL HOSPITAL   (Singapore)

^o UNIVERSITY OF SANTO TOMAS   (Philippines)

^p CHULALONGKORN UNIVERSITY   (Thailand)

^q PAMELA YOUDE NETHERSOLE EASTERN HOSPITAL   (Hong Kong)

more..

Author keywords

Boosters; Hepatitis B; Immunization

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B VACCINE;

ANTIBODY PRODUCTION; ASIA; CLINICAL PRACTICE; ENDEMIC DISEASE; HEALTH CARE PERSONNEL; HEPATITIS B; HEPATITIS B VIRUS; HIGH RISK POPULATION; HUMAN; IMMUNE DEFICIENCY; IMMUNITY; PRACTICE GUIDELINE; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; VACCINATION;

EID: 19944432774     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2004.03398.x     Document Type: Review

References (46)

1. Huang LM, Chiang BL, Lee CY, Lee PI, Chi WK, Chang MH. Long-term response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen. Hepatology 1999; 29: 954-9.
2. West DJ, Calandra GB. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine 1996; 14: 1019-27.
3. Yang TY, Huang LM, Lee CY, Chiang BL, Hsu HM, Chi WK. Humoral and cellular immunity after 15 years of hepatitis B vaccination. 166th Scientific Meeting of the Chinese Taipei Pediatric Association 7-8 April 2001, Taipei, Taiwan, ROC. Abstract No. 59.
4. Immunization Practices Advisory Committee. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Morb. Mortal. Wkly Rep. 1991; 40 (RR-13): 1-19.
5. Wismans PJ, van Hattum J, De Gast GC et al. The spot-ELISA: a sensitive in vitro method to study the immune response to hepatitis B surface antigen. Clin. Exp. Immunol. 1989; 78: 75-9.
6. European Consensus Group on Hepatitis B. Immunity. Are boosters needed for lifelong hepatitis B immunity? Lancet 2000; 355: 561-5.
7. Banatvala JE, Van Damme P. Hepatitis B vaccine - do we need boosters? J. Viral. Hepat. 2003; 10: 1-6.
8. Thompson SC, Norris M. Hepatitis B vaccination of personnel employed in Victorian hospitals: are those at risk adequately protected? Infect. Control Hosp. Epidemiol. 1999; 20: 51-4.
9. Barash C, Conn MI, DiMarino AJ, Marzano J, Allen ML. Serological hepatitis B immunity in vaccinated health care workers. Arch. Intern. Med. 1999; 159: 1481-3.
10. Davies GR, Porra M. The need for post-vaccination serology and the timing of booster vaccinations against hepatitis B in dental health care workers. Aust. Dent. J. 1994; 39: 238-41.
11. Girndt M, Köhler H. Hepatitis B virus infection in hemodialysis patients. Semin. Nephrol. 2002; 22: 340-50.
12. Kletzmayr J, Watschinger B. Chronic hepatitis B virus infection in renal transplant recipients. Semin. Nephrol. 2002; 22: 375-89.
13. Yetgin S, Tunç B, Koc A, Toksoy HB, Ceyhan M, Kanra G. Two booster dose hepatitis B virus vaccination in patients with leukemia. Leuk. Res. 2001; 25: 647-9.
14. Chlabicz S, Grzeszczuk A. Hepatitis B virus vaccine for patients with hepatitis C virus infection. Infection 2000; 28: 341-5.
15. Cassidy WM. Adolescent hepatitis B vaccination: a review. Minerva Pediatr. 2001; 53: 559-66.
16. Stark K, Bienzle U, Vonk R, Guggenmoos-Holzmann I. History of syringe sharing in prison and risk of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection among injecting drug users in Berlin. Int. J. Epidemiol. 1997; 26: 1359-66.
17. Hall AJ. Hepatitis B vaccination: protection for how long and against what? Br. Med. J. 1993; 307: 276-7.
18. Andre F. Hepatitis B epidemiology in Asia, the Middle East and Africa. Vaccine 2000; 18: S20-2.
19. Kane MA. Status of hepatitis B immunization programs in 1998. Vaccine 1998; 16: S104-8.
20. National Advisory Committee on Immunization. Revised guidelines for booster vaccination against hepatitis B. Can. Med. Assoc. J. 1992; 147: 1029-30.
21. Zannolli R, Morgese G. Hepatitis B vaccine: current issues. Ann. Pharmacother. 1997; 31: 1059-67.
22. Struve J, Aronsson B, Frenning B, Granath F, von Sydow M, Weiland O. Intramuscular versus intradermal administration of a recombinant hepatitis B vaccine: a comparison of response rates and analysis of factors influencing the antibody response. Scand. J. Infect Dis. 1992; 24: 423-9.
23. Bryan JP, Sjogren MH, Perine PL, Legters LJ. Low-dose intradermal and intramuscular vaccination against hepatitis B. Clin. Infect. Dis. 1992; 14: 697-707.
24. Clemens R, Sanger R, Kruppenbacher J et al. Booster immunization of low- and non-responders after a standard three dose hepatitis B vaccine schedule - results of a post-marketing surveillance. Vaccine 1997; 15: 349-52.
25. Struve J, Aronsson B, Frenning B, Forsgren M, Weiland O. Response to a booster dose 18 months after a low anti-HBs response (10-99 IU/L) to three doses of intradermally or intramuscularly administered recombinant hepatitis B vaccine. Infection 1995; 23: 42-5.
26. Poovorawan Y, Theamboonlers A, Hirsch P et al. Persistence of antibodies to the surface antigen of the hepatitis B virus (anti-HBs) in children subjected to the Expanded Programme on Immunization (EPI), including hepatitis-B vaccine, in Thailand. Ann. Trop. Med. Parasitol. 2000; 94: 615-21.
27. Salmond CE, Bandaranayake DR, Tobias M. Immunity to hepatitis B in two birth cohorts given plasma-derived or yeast-derived vaccine. NZ Med. J. 1999; 112: 331-3.
28. Chadha MS, Arankalle VA. Ten-year serological follow up of hepatitis B vaccine recipients. Indian J. Gastroenterol. 2000; 19: 168-71.
29. Watson B, West DJ, Chilkatowsky A, Piercy S, Ioli VA. Persistence of immunologic memory for 13 years in recipients of a recombinant hepatitis B vaccine. Vaccine 2001; 19: 3164-8.
30. Chongsrisawat V, Theamboonlers A, Khwanjaipanich S, Owatanapanich S, Sinlaparatsamee S, Poovorawan Y. Humoral immune response following hepatitis B vaccine booster dose in children with and without prior immunization. Southeast Asian J. Trop. Med. Public Health 2000; 31: 623-6.
31. Dentico P, Crovari P, Lai PL et al. Anamnestic response to administration of purified non-absorbed hepatitis B surface antigen in healthy responders to hepatitis B vaccine with long-term non-protective antibody titres. Vaccine 2002; 20: 3725-30.
32. Whittle H, Jaffar S, Wansbrough M et al. Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. Br. Med. J. 2002; 325: 569-73.
33. Young BWY, Lee SS, Lim WL, Yeoh EK. The long-term efficacy of plasma-derived hepatitis B vaccine in babies born to carrier mothers. J. Viral. Hepat. 2003; 10: 23-30.
34. Wu W, Sun C, Jiang M et al. Long-term efficacy of vaccination against hepatitis B in newborns: 13 years' follow-up. Chinese J. Exp. Clin. Virol. 2001; 15: 239-41.
35. Xia G, Jia Z, Yan T et al. Long-term efficacy and persistence of Chinese infants after receiving only active plasma-derived hepatitis B vaccine. Chinese J. Exp. Clin. Virol. 2002; 16: 146-9.
36. Liao SS, Li RC, Li H et al. Long-term efficacy of plasma-derived hepatitis B vaccine: a 15-year follow-up study among Chinese children. Vaccine 1999; 14: 2661-6.
37. Xueliang W, Huiwen X, Guihua Z. Long-term efficacy and immunological memory of plasma-derived hepatitis B vaccine 11 years after initial inoculation. J. Xi'an Med. Univ. 2000; 12: 122-5.
38. Poovorawan Y, Sanpavat S, Pongpunglert W et al. Long term efficacy of hepatitis B vaccine in infants born to hepatitis B e antigen-positive mothers. Pediatr. Infect. Dis. J. 1992; 11: 816-21.
39. Coursaget P, Leboulleux D, Soumare M et al. Twelve-year follow-up study of hepatitis B immunization of Senegalese infants. J. Hepatol. 1994; 21: 250-4.
40. Coursaget P, Yvonnet B, Chotard J et al. Seven-year study of hepatitis B vaccine efficacy in infants from an endemic area (Senegal). Lancet 1986; 2: 1143-5.
41. Lieming D, Mintai Z, Yinfu W, Shaochon Z, Weiqin K, Smego RA Jr. A 9-year follow-up study of the immunogenicity and long-term efficacy of plasma-derived hepatitis B vaccine in high-risk Chinese neonates. Clin. Infect. Dis. 1993; 17: 475-9.
42. Lee PI, Lee CY, Huang LM, Chang MH. Long-term efficacy of recombinant hepatitis B vaccine and risk of natural infection in infants born to mothers with hepatitis B e antigen. Paediatrics 1995; 126: 716-21.
43. Safary A, Beck J. Chronic viral hepatitis and liver cirrhosis. Vaccination against hepatitis B. current challenges for Asian countries and future directions. J. Gastroenterol. Hepatol. 2000; 15: 396-401.
44. Cacciola I, Pollicino T, Squadrito G et al. Occult hepatitis B infection in patients with chronic hepatitis C liver disease. N. Engl. J. Med. 1999; 341: 22-6.
45. Chen DS. Towards control of hepatitis B in the Asia-Pacific region. Public health measures to control hepatitis B virus infection in the developing countries of the Asia-Pacific region. J. Gastroenterol. Hepatol. 2000; 15 (Suppl.): E7-10.
46. Trepo CG, Prince AM. Absence of complete homologous immunity in hepatitis B infection after massive exposure. Ann. Intern. Med. 1976; 85: 427-30.